No amount is too small
Empty box
In adult blood cancer patients whose conditions are under control and are regularly assessed by their doctors, continuing with the same effective treatment as basic standard of care is often necessary.
The Patient Care Fund is a partnership between Ray of Hope [ROH] and Johnson & Johnson Pte Ltd to provide partial financial assistance (up to $1600/month) to eligible adult blood cancer patients who are affected by the national cancer policy changes from 1 September 2022. This is to ensure that eligible patients who have financial constraints can continue on their treatments.
Eligibility and next steps
1. What is this program about?
This is a partial financial assistance program to help eligible adult blood cancer patients continue on existing effective treatment after the national cancer policy change on 1 September 2022. The program will ensure that eligible patients that are financially constrained can continue on their treatment.
2. Why is Ray of Hope providing this program?
Ray of Hope is a crowdfunding charity and an Institute of Public Character (IPC). We exist to meet the genuine needs of individuals and families who have fallen through the cracks in our society’s safety nets and policies. This patient care fund will enable patients to continue treatment by providing partial financial assistance to some adult blood cancer patients who are affected by the national cancer policy changes from 1 September 2022.
3. Are there other sponsors in this program?
Ray of Hope is administering this program independently. This program is supported by a grant from Johnson & Johnson Pte Ltd.
4. Which treatments are covered by this program?
Patients with certain blood cancers who are prescribed with Daratumumab and Ibrutinib and are using them according to product label are eligible to apply.
5. How long does each subsidy approval last?
Each application when approved will cover the treatment cost for 3 months. Patients who have been assessed by doctors and require continuation of treatment can reapply for this fund.
6. What happens if I still cannot afford my medicines even after receiving support from this program?
Patients can consult their doctor and/or hospital medical social worker for assistance.
7. How long will this program last?
This program is intended to help existing patients who are affected by the cancer drug policy change on 1 September 2022. Please consult your doctor and/or medical social worker for more information.
8. What happens if the doctor stops my treatment?
A patient’s eligibility for this fund will stop once the patient stops receiving treatment with either Daratumumab or Ibrutinib.